Phase 3 trials of anti-COVID drug Molnupiravir begins
The Hindu
‘Pre-clinical trials showed remarkable reduction in SARS-COV-2 load’
Yashoda Hospitals, Somajiguda, in association with Natco Pharma announced the commencement of oral administration of Molnupiravir phase III clinical trials for patients with mild and moderate COVID-19 symptoms, following the nod of the Drugs Controller General of India on Friday. The clinical trials will entail the COVID patient volunteers to take 400 mg twice a day without being admitted in hospital since it is an out-patient department-based clinical trial, and have regular interactions with their physicians on day 5, day 10 and day 15 for their follow-up cycle at the hospital.More Related News
India train in 'Big Apple': Getting used to cooler temperatures, playing white-ball games in morning
Virat Kohli takes break, Indian cricket team prepares for T20 World Cup in New York with morning training sessions.